Chinese a Nti鄄 Cancer a Ssociation
暂无分享,去创建一个
[1] E. Shin,et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.
[2] L. Doyle,et al. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.
[3] Daniel J Garry,et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. , 2004, Developmental biology.
[4] E. Barta,et al. Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.
[5] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[6] D. Ross,et al. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. , 2006, Blood.
[7] R. Kim,et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.
[8] D. Sullivan,et al. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. , 2006, Cancer research.
[9] Martin G. Pomper,et al. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. , 2009, Cancer research.
[10] C. Hrycyna,et al. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. , 2005, Biochemistry.
[11] R. Robey,et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.
[12] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[13] G. Superti-Furga,et al. Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib. , 2007 .
[14] M. Raaijmakers,et al. Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia , 2005, Clinical Cancer Research.
[15] T. Ishikawa,et al. Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro , 2009, Pharmaceutical Research.
[16] Jos H Beijnen,et al. Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.
[17] I. Shiojima,et al. Akt Signaling Regulates Side Population Cell Phenotype via Bcrp1 Translocation* , 2003, Journal of Biological Chemistry.
[18] U. Völker,et al. EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP) , 2006, Drug Metabolism and Disposition.
[19] D. Boschelli,et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.
[20] J. Ware,et al. Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.
[21] T. Ishikawa,et al. Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. , 2009, Advanced drug delivery reviews.
[22] S. Bates,et al. Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma , 2006, Molecular and Cellular Biology.
[23] H. Nakauchi. Isolation and Clonal Characterization of Hematopoietic and Liver Stem Cells , 2004, Cornea.
[24] M. B. Davis,et al. breast cancer cells , 2009 .
[25] Y. Wang,et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells , 2007, Leukemia.
[26] T. Fojo,et al. Increased MDR 1 Expression in Normal andMalignant Peripheral BloodMononuclear Cells Obtained from Patients Receiving Depsipeptide ( FR 901228 , FK 228 , NSC 630176 ) , 2006 .
[27] Vincenzo,et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.
[28] M. Pomper,et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. , 2007, Cancer research.
[29] J. Schellens,et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.
[30] Y. Assaraf,et al. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. , 2009, Neoplasia.
[31] Y. Sugimoto,et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.
[32] Yi Zhang,et al. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. , 2006, American journal of physiology. Endocrinology and metabolism.
[33] B. Dijkmans,et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα , 2004, Annals of the rheumatic diseases.
[34] T. Litman,et al. Identification of Intra- and Intermolecular Disulfide Bridges in the Multidrug Resistance Transporter ABCG2* , 2005, Journal of Biological Chemistry.
[35] I. Pastan,et al. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. , 1987, The Journal of biological chemistry.
[36] A. Calcagno,et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor , 2006, Molecular Cancer Therapeutics.
[37] D. Ross,et al. Impact of breast cancer resistance protein on cancer treatment outcomes. , 2010, Methods in molecular biology.
[38] Joseph W. Polli,et al. An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.
[39] M. Pirmohamed,et al. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters , 2009, Leukemia.
[40] E. Rego,et al. Determination of P‐glycoprotein, MDR‐related protein 1, breast cancer resistance protein, and lung‐resistance protein expression in leukemic stem cells of acute myeloid leukemia , 2008, Cytometry. Part B, Clinical cytometry.
[41] H. Berenbaum,et al. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. , 2006, Blood.
[42] T. Powles,et al. A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP , 2010, Molecular Cancer Therapeutics.
[43] T. Ishikawa,et al. Disruption of N‐linked glycosylation enhances ubiquitin‐mediated proteasomal degradation of the human ATP‐binding cassette transporter ABCG2 , 2009, The FEBS journal.
[44] Hong-Bin Fang,et al. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. , 2003, Molecular pharmacology.
[45] Q. Zhu,et al. Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. , 1994, Cancer research.
[46] B. Torok-Storb,et al. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.
[47] J. Meijerink,et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) , 2002, Leukemia.
[48] Jos H. Beijnen,et al. Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.
[49] Shusen Zheng,et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. , 2008, Carcinogenesis.
[50] Yuichi Sugiyama,et al. Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.
[51] V. P. Savitski,et al. CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34− cells in childhood AML , 2008, Annals of Hematology.
[52] David S. Miller,et al. 17-β-Estradiol: A Powerful Modulator of Blood–Brain Barrier BCRP Activity , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[53] Y. Miki,et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.
[54] S. Bates,et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. , 2002, Blood.
[55] Mariël Brok,et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.
[56] Sagar Agarwal,et al. The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.
[57] T. Utsunomiya,et al. Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.
[58] P. Sonneveld,et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age , 2007, Annals of Hematology.
[59] Jian-hua Chang,et al. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. , 2007, Carcinogenesis.
[60] D. Rigal,et al. Transcriptional Regulation of the Human MDR1 Gene at the Level of the Inverted MED‐1 Promoter Region , 2002, Annals of the New York Academy of Sciences.
[61] R. Fanin,et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. , 2006, Haematologica.
[62] O. van Tellingen,et al. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. , 2003, Cancer research.
[63] T. Tsuruo,et al. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. , 2003, Molecular cancer therapeutics.
[64] S. Rabindran,et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.
[65] T. Ince,et al. Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells. , 1995, Gene.
[66] T. Ince,et al. A Conserved Downstream Element Defines a New Class of RNA Polymerase II Promoters (*) , 1995, Journal of Biological Chemistry.
[67] K. Iseki,et al. Expression Level of ABCG2 in the Placenta Decreases from the Mid Stage to the End of Gestation , 2005, Bioscience, biotechnology, and biochemistry.
[68] Francisco Gamarro,et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.
[69] O. Legrand,et al. Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.
[70] H. Minderman,et al. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023 , 2004, Cancer Chemotherapy and Pharmacology.
[71] E. Schuetz,et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.
[72] A. Reichel,et al. N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[73] J. Schuetz,et al. The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.
[74] N. Shaik,et al. P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.
[75] J. Rubnitz,et al. Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. , 2011, Leukemia research.
[76] L. Doyle,et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.
[77] A. Schinkel,et al. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. , 2011, Molecular pharmaceutics.
[78] R. Marks,et al. Squamous cell carcinoma , 1996, The Lancet.
[79] P. Leung,et al. Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells , 2008, Molecular Pharmacology.
[80] T. Fojo,et al. Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines , 2000, Genes, chromosomes & cancer.
[81] A. V. van Herwaarden,et al. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. , 2006, Carcinogenesis.
[82] M. Ballmaier,et al. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line , 2007, Molecular and Cellular Biochemistry.
[83] K. Noguchi,et al. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. , 2009, Advanced drug delivery reviews.
[84] T. Tsuruo,et al. Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization , 2002, International journal of cancer.
[85] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[86] J. Mohler,et al. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. , 2005, Cancer research.
[87] C. D. Salcido,et al. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes , 2008, British Journal of Cancer.
[88] F. Segal,et al. A CHARACTERIZATION OF FIBRANT SEGAL CATEGORIES , 2006, math/0603400.
[89] C. Higgins,et al. The ABC of channel regulation , 1995, Cell.
[90] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[91] J. Schellens,et al. Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications , 2000, Annals of the New York Academy of Sciences.
[92] S. Bates,et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.
[93] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] Thomas Ried,et al. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.
[95] T. Ishikawa,et al. Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2 , 2007, Cancer science.
[96] L. M. Wang,et al. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. , 2010, Mini reviews in medicinal chemistry.
[97] S. Steinberg,et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] T. Litman,et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.
[99] M. Gasparetto,et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.
[100] E. Hudson,et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.
[101] A. Fojo,et al. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. , 1990, The Journal of biological chemistry.
[102] Zhe-Sheng Chen,et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.
[103] G. Alí,et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. , 2011, Neoplasia.
[104] J. Keelan,et al. Independent Regulation of Apical and Basolateral Drug Transporter Expression and Function in Placental Trophoblasts by Cytokines, Steroids, and Growth Factors , 2007, Drug Metabolism and Disposition.
[105] T. Janvilisri,et al. Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis* , 2003, Journal of Biological Chemistry.
[106] I. Catalá,et al. Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.
[107] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[108] S. Baker,et al. Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters , 2009, Clinical Cancer Research.
[109] K. Maeda,et al. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.
[110] D. B. Duignan,et al. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. , 2006, Molecular pharmaceutics.
[111] S H Kaufmann,et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.
[112] Stephen Lam,et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.
[113] G. Kéri,et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.
[114] H. Kusuhara,et al. Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1. , 2011, Biochemical and biophysical research communications.
[115] Yuichi Sugiyama,et al. ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.
[116] Jos H Beijnen,et al. Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.
[117] Xin Li,et al. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. , 2011, Biochemical pharmacology.
[118] T. Ishikawa,et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.
[119] H. Aburatani,et al. Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells , 2011, Oncogene.
[120] Rudolf Jaenisch,et al. Ectopic Expression of Oct-4 Blocks Progenitor-Cell Differentiation and Causes Dysplasia in Epithelial Tissues , 2005, Cell.
[121] A. Schinkel,et al. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.
[122] Linhao Li,et al. A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. , 2010, Biochemical pharmacology.
[123] Yehuda G. Assaraf,et al. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates , 2006, Cancer Chemotherapy and Pharmacology.
[124] F. Zunino,et al. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. , 2007, Biochemical pharmacology.
[125] M. Wierdl,et al. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. , 2003, Molecular pharmacology.
[126] W. T. Beck,et al. Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.
[127] E. Giovannetti,et al. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco‐2 cells , 2008, International journal of cancer.
[128] Sharon Marsh,et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.
[129] A. S. Conner,et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.
[130] B. Leyland-Jones,et al. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling , 2010, British Journal of Cancer.
[131] Fei Li,et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. , 2002, Cancer research.
[132] L. Doyle,et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. , 2000, Blood.
[133] A. Masamune,et al. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2 , 2012, Journal of cellular physiology.
[134] Ruoping Tang,et al. MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia , 2005, Clinical Cancer Research.
[135] F. Morabito,et al. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. , 2004, Leukemia research.
[136] Jing Li,et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.
[137] M. Lübbert,et al. Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes , 2009, Clinical Cancer Research.
[138] I. Hidalgo,et al. Application and limitation of inhibitors in drug-transporter interactions studies. , 2008, International journal of pharmaceutics.
[139] Alexei A. Sharov,et al. Dissecting Oct3/4-Regulated Gene Networks in Embryonic Stem Cells by Expression Profiling , 2006, PloS one.
[140] D. Miller,et al. Estrogen Receptor β Signaling through Phosphatase and Tensin Homolog/Phosphoinositide 3-Kinase/Akt/Glycogen Synthase Kinase 3 Down-Regulates Blood-Brain Barrier Breast Cancer Resistance Protein , 2010, Journal of Pharmacology and Experimental Therapeutics.
[141] M. Tan,et al. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[142] Suneet Shukla,et al. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. , 2011, Molecular pharmaceutics.
[143] E. Henderson,et al. Lymphoblastic leukaemia. , 1969, British medical journal.
[144] W. Kamps,et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[145] Y. Miki,et al. C 421 A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q 141 K Protein and Low-Level Drug Resistance 1 , 2002 .
[146] S. Emanuel,et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.
[147] L. Doyle,et al. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. , 1996, Leukemia.
[148] Hui Peng,et al. A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer Chemotherapy , 2009, PloS one.
[149] Hailong Wu,et al. Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype , 2010, Molecular Cancer Therapeutics.
[150] Y. Miao,et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations , 2010, British Journal of Cancer.
[151] M Dietel,et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. , 1999, Journal of the National Cancer Institute.
[152] W. T. Beck,et al. Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. , 2011, Biochimica et biophysica acta.
[153] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[154] F. S. Pardo,et al. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. , 2008, Archives of otolaryngology--head & neck surgery.
[155] J. Verweij,et al. Effect of ABCG2 genotype on the oral vioavailability of topotecan , 2005, Cancer biology & therapy.
[156] G. Szakács,et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.
[157] Jing Wang,et al. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. , 2009, Stem cells and development.
[158] W. Greco,et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function , 2004, Leukemia.
[159] N. Sundarraj,et al. Multipotent Stem Cells in Human Corneal Stroma , 2004, Stem cells.
[160] D. Steinbach,et al. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia , 2002, British journal of haematology.
[161] Peter J Houghton,et al. Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.
[162] X. Ronot,et al. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). , 2005, Journal of medicinal chemistry.
[163] Ha-won Jeong,et al. SALL4, a Stem Cell Factor, Affects the Side Population by Regulation of the ATP-Binding Cassette Drug Transport Genes , 2011, PloS one.
[164] I. Pastan,et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[165] T. Fojo,et al. Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) , 2006, Clinical Cancer Research.
[166] S. Kohno,et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. , 2005, Cancer research.
[167] J. Schellens,et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice , 2008, Molecular Cancer Therapeutics.
[168] S. Bates,et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. , 2003, Cancer research.
[169] H. Rosing,et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[170] H. Bartsch,et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients , 2009, International journal of cancer.
[171] Yong-Hae Han,et al. Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells , 2008, Pharmaceutical Research.
[172] P. Watkins,et al. Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms , 2008, Drug Metabolism and Disposition.
[173] Yasuaki Yamada,et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[174] S. Bates,et al. Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2* , 2004, Journal of Biological Chemistry.
[175] Suneet Shukla,et al. Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.
[176] Alfonso Lampen,et al. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. , 2005, Carcinogenesis.
[177] S. Bates,et al. Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells , 2008, Molecular Cancer Research.
[178] P. Boutros,et al. Aryl Hydrocarbon Receptor Is a Transcriptional Activator of the Human Breast Cancer Resistance Protein ( BCRP / ABCG 2 ) , 2010 .
[179] Fang Wang,et al. Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function , 2009, PloS one.
[180] M. Leggas,et al. Progesterone Acts via Progesterone Receptors A and B to Regulate Breast Cancer Resistance Protein Expression , 2008, Molecular Pharmacology.
[181] V. Ling,et al. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. , 2008, Experimental hematology.
[182] Eun-Young Kim,et al. Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population , 2007, Drug Metabolism And Disposition.
[183] M. Barrand,et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.
[184] A. Zannettino,et al. Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity , 2010, Leukemia.
[185] Cynthia S. Johnson,et al. Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis , 2006, Clinical Cancer Research.
[186] H. Kotani,et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. , 2001, Cancer research.
[187] J. Melo,et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.
[188] Xiaokun Cai,et al. Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. , 2010, International journal of biochemistry and molecular biology.
[189] J. Wang-Rodriguez,et al. EGFR Regulates the Side Population in Head and Neck Squamous Cell Carcinoma , 2006, The Laryngoscope.
[190] J. DiMaio,et al. Cellular and Molecular Regulation of Skeletal Muscle Side Population Cells , 2004, Stem cells.
[191] Jiang Zhu,et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials , 2008, Journal of Cancer Research and Clinical Oncology.
[192] B. Sorrentino,et al. Expression of Mouse Abcg2 mRNA during Hematopoiesis Is Regulated by Alternative Use of Multiple Leader Exons and Promoters* , 2006, Journal of Biological Chemistry.
[193] S. Bates,et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. , 2007, Cancer research.
[194] S. Dhakshinamoorthy,et al. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. , 2000, Current topics in cellular regulation.
[195] E. Kis,et al. Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. , 2009, Biological & pharmaceutical bulletin.
[196] H. Burris,et al. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.
[197] Ming-Rong Zhang,et al. [11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. , 2011, Bioorganic & medicinal chemistry letters.
[198] A. Hofman,et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study , 2008, The Lancet.
[199] Y. Sugimoto,et al. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. , 2005, Cancer research.
[200] J. Schellens,et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.
[201] M. Andreeff,et al. Low levels of ABCG2 expression in adult AML blast samples. , 2002, Blood.
[202] P. Lu,et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway , 2010, Hepatology.
[203] A. Seidel,et al. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[204] B. Luo,et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. , 2009, Neoplasma.
[205] Y. Sugiyama,et al. REGULATION OF THE CELL SURFACE EXPRESSION OF HUMAN BCRP/ABCG2 BY THE PHOSPHORYLATION STATE OF AKT IN POLARIZED CELLS , 2005, Drug Metabolism and Disposition.
[206] M. Goodell,et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[207] F. Boussin,et al. Neural stem cells from mouse forebrain are contained in a population distinct from the ‘side population’ , 2006, Journal of neurochemistry.
[208] Marilyn E Morris,et al. MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.
[209] S. Bates,et al. Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway , 2011, Molecular Cancer Research.
[210] Sagar Agarwal,et al. Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.
[211] K. Kondo,et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8 , 2002, Journal of Human Genetics.
[212] Shaoxiang Zhang,et al. MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.
[213] Fang Wang,et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. , 2010, Cancer research.
[214] K. Motojima,et al. PPARα Agonists Positively and Negatively Regulate the Expression of Several Nutrient/Drug Transporters in Mouse Small Intestine , 2007 .
[215] T. Ishikawa,et al. Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. , 2006, Journal of experimental therapeutics & oncology.
[216] S. Bates,et al. Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.